In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hunting For Unicorns: Starton Therapeutics

Clinical-stage biopharma Starton Therapeutics is developing continuous delivery systems and transdermal technologies to improve the safety and efficacy of existing cancer medications, and eschewing VC firms in favor of retail investors. Chair and CEO Pedro Lichtinger recently appeared on Unicorn Hunters, an online reality TV show, to pitch the company to celebrity judges, and the public at large.

Business Strategies Commercial Financing

Nucleome Looks To Decode The ‘Dark Genome’ With New Technology

Despite accounting for 98% of our DNA, the ‘dark genome’ has yet to be effectively harnessed for drug discovery. Nucleome Therapeutics’ new modeling technology could finally provide the tools that have been missing, says CEO Danuta Jeziorska.

Platform Technologies Research and Development Strategies Artificial Intelligence

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development


Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Boehringer Ingelheim: 1885 To Present

Founded in 1885 by Albert Boehringer and now comprised of 146 affiliated companies worldwide and a workforce of roughly 50,000 people, Boehringer Ingelheim has stood the test of time.

Companies BioPharmaceutical

The Vital Role Of Start-Ups In Medtech Innovation

Focus On Switzerland – Part 4: The fragile nature of start-ups belies their value in medtech innovation, and they do not need unnecessary regulatory complications.

Switzerland StartUps and SMEs

Top 10 Best-Selling Drugs Of 2020

One hundred billion dollars. That is the combined revenue of the top 10 pharmaceuticals in 2020, marking the first year in which this threshold has been crossed. AbbVie’s Humira easily retained its lead in 2020 with $20.3bn in sales. Gilead Sciences’ HIV triple combo Biktarvy was the fastest climber, entering the top 10 in eighth place after 53.2% growth in a year, while Avastin, Enbrel and Rituxan fell out of the list.

Companies Growth

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Medtech’s Place In Health Care R&I Boosted Under Horizon Europe

Cross-industry collaboration is the new focus of EU health care technology research funding activity. Under Horizon Europe, the Innovative Health Initiative will encourage convergence in health technology, and prioritize digital technologies and data analytics. No longer can EU-funded projects be pharma-only or medtech-only, said MedTech Europe’s Patrick Boisseau.

EU Medical Device

Immunomodulating Heat-Killed Bacteria Could Become Staple Of Oncology Treatment

UK-based Immodulon Therapeutics is developing novel immunomodulators in the form of heat-killed bacteria, being trialed in combination with other cancer treatments such as checkpoint inhibitors. The biotech is initially looking at underserved areas, including pancreatic cancer.

C-Suite Speaks ImmunoOncology

Designing A Better Future For Immuno-Oncology: The Power Of ‘Iterative Innovation’

We are at a pivotal point in the reassessment of our approach to innovation, with the value of ‘design thinking’ and an ‘iterative innovation approach’ becoming the most promising solutions to solving the scientific and biological challenges of the future.

C-Suite Speaks ImmunoOncology
Data Spotlight

Boehringer Ingelheim: 1885 To Present

Founded in 1885 by Albert Boehringer and now comprised of 146 affiliated companies worldwide and a workforce of roughly 50,000 people, Boehringer Ingelheim has stood the test of time.

Titans Of Pharma 2021: J&J’s Gorsky Tops Big Pharma Remuneration

A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.

Top 10 Best-Selling Drugs Of 2020

One hundred billion dollars. That is the combined revenue of the top 10 pharmaceuticals in 2020, marking the first year in which this threshold has been crossed. AbbVie’s Humira easily retained its lead in 2020 with $20.3bn in sales. Gilead Sciences’ HIV triple combo Biktarvy was the fastest climber, entering the top 10 in eighth place after 53.2% growth in a year, while Avastin, Enbrel and Rituxan fell out of the list.

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

136 Years And Counting: Boehringer Ingelheim Sees Advantage In Private Structure

The family-owned German pharma dates back to 1885 and tries to keep up with its publicly traded peers by not mimicking everything they do, but with a “value by innovation” focus.

Companies Business Strategies

On-Demand Robotics The Way Forward In Minimally Invasive Surgery

Focus On Switzerland – Part 3: Robotics means different things to different surgeons, according to Swiss innovator Distalmotion, whose surgical robot combines with laparoscopy to leave the surgeon fully in control in the OR.

Switzerland Gynecology & Urology

Medtronic Looks Beyond The World Of Doctors And Devices In New Approach To Markets

Focus On Switzerland – Part 2. Health warning to global medtechs: the world’s largest medtech company is taking steps to strengthen key account management, retain its market share hold and set up new health care partnerships.

Europe Switzerland

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Biosimilar Interchangeability: A Blessing Or A Curse?

Biosimilar interchangeability is a hot topic in the US, with the first FDA decision on a formal interchangeability designation expected this month. But across the industry, views differ dramatically on the desirability and likely impact of this additional standard to biosimilarity.

US States Biosimilars

Experience Counts When Shaping Policy Strategies

Hayden Kennedy, AbbVie’s VP of global policy and US access strategies, and one of In Vivo’s 2021 Rising Leaders, shares her approach to tackling gender diversity and discusses how a background in government has helped shape her thinking in pharma.

Business Strategies Commercial

Aduhelm Shockwaves Will Reverberate Across Industry

The butterfly effect is an elegant analogy to describe the seemingly unpredictable and far-reaching implications of a relatively small and inconsequential event. The FDA’s approval of Aduhelm is not so much a butterfly gently flapping its wings, but rather a sonic boom emanating from a jet engine. Most immediately, it provides a new therapeutic option for millions of patients in dire need of hope, vindicating Biogen’s faith with a revenue stream running into many billions of dollars. Longer-term the reverberations may be felt across the entire industry, throwing into question the evidentiary requirement for drug development.

Approvals Clinical Trials

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Deals In Depth: June 2021

Six $1bn+ alliances were penned in June. Topping the list was Eisai’s potential $3.1bn collaboration Bristol-Myers Squibb for the co-development and co-commercialization of Eisai’s antibody drug conjugate MORAb-202 in Japan, China, select countries in the Asia-Pacific region, the US, Canada, Europe (including the EU and UK), and Russia. The candidate is in Phase I in Japan and Phase I/II in the US for anti-folate receptor alpha-positive solid tumors.

Deals Financing

The Vital Role Of Start-Ups In Medtech Innovation

Focus On Switzerland – Part 4: The fragile nature of start-ups belies their value in medtech innovation, and they do not need unnecessary regulatory complications.

Switzerland StartUps and SMEs

Medtech Innovation And Reinvention Is Part Of The Swiss DNA

Focus On Switzerland – Part 1: Switzerland is a high-tech microcosm of the medtech industry. It is home to the EMEA headquarters of the world’s largest medtech group, Medtronic, and supports a vibrant SME and start-up community, in the example of hybrid soft tissue robotics company Distalmotion. In Vivo interviewed both for this feature on the contribution of Swiss medtech in the advancement of patient care, domestically and globally.

Switzerland Innovation
UsernamePublicRestriction

Register